Emerging studies suggest this peptide, a dual stimulator targeting both incretin and glucose-dependent insulinotropic polypeptide , appears to offer a promising step forward for body management . Preliminary clinical trials have shown substantial losses in visceral tissue, conceivably outperforming existing body composition therapies . Despite this